Michael Fralick MD, PhD, MSc, FRCPC

Dr. Michael Fralick is a board-certified General Internist in Canada and the United States. He works at Mount Sinai Hospital in Toronto as a Clinician Scientist where he attends the General Internal Medicine inpatient service, and locums in The Sault Area Hospital in Sault Ste Marie, Ontario. He is also an affiliated faculty member of the Program On Regulation Therapeutics And Law (PORTAL) at the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham and Women’s Hospital.

He completed his medical degree and internal medicine residency training at the University of Toronto. He then completed a Master’s of Science in Clinical Epidemiology at Harvard University including a research fellowship in Pharmacoepidemiology at Division of Pharmacoepidemiology and Pharmacoeconomics and a fellowship in Health Policy with PORTAL. His Ph.D., completed at the University of Toronto under the supervision of Dr. Don Redelmeier, focused on the intersection between machine learning and pharmacoepidemiology. It utilized data from the United States to understand the safety and effectiveness of SGLT2 inhibitors for adults with diabetes.

He splits his research time between GEMINI and LKS-CHART and plans to integrate pharmacoepidemiology with Machine Learning to understand the safety and effectiveness of medications for adults with diabetes and cardiovascular disease.